|
Video: What is a Stock Split?
|
|
Nuvectis Pharma is a biopharmaceutical company focused on the development of medicines for the treatment of medical needs in oncology. Co. uses target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Co. is developing two preclinical drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 pathway. NXP800 targets ovarian clear cell carcinoma and endometrioid ovarian cancer. NXP900 is an oral small molecule designed to inhibit the SRC and YES1 kinases. NXP900 is in preclinical development with IND-enabling studies. According to our Nuvectis Pharma stock split history records, Nuvectis Pharma has had 0 splits. | |
|
Nuvectis Pharma (NVCT) has 0 splits in our Nuvectis Pharma stock split history database.
Looking at the Nuvectis Pharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Nuvectis Pharma shares, starting with a $10,000 purchase of NVCT, presented on a split-history-adjusted basis factoring in the complete Nuvectis Pharma stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/07/2022 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$7.95 |
|
End price/share: |
$6.50 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-18.24% |
|
Average Annual Total Return: |
-8.70% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$8,175.12 |
|
Years: |
2.21 |
|
|
|
|
|